1.
J Hepatol
; 74(5): 1243-1244, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1093094
Subject(s)
Bile Duct Diseases , COVID-19 , Drug Monitoring/methods , End Stage Liver Disease , Ketamine , Respiration, Artificial/methods , Administration, Intravenous , Anesthetics, Dissociative/administration & dosage , Anesthetics, Dissociative/adverse effects , Bile Duct Diseases/blood , Bile Duct Diseases/chemically induced , Bile Duct Diseases/pathology , Bile Duct Diseases/therapy , Biopsy/methods , COVID-19/epidemiology , COVID-19/therapy , Dose-Response Relationship, Drug , Duration of Therapy , End Stage Liver Disease/chemically induced , End Stage Liver Disease/diagnosis , End Stage Liver Disease/mortality , Female , France/epidemiology , Germany/epidemiology , Humans , Ketamine/administration & dosage , Ketamine/adverse effects , Liver Function Tests/methods , Male , Middle Aged , Outcome and Process Assessment, Health Care , SARS-CoV-2
2.
Hepatology
; 74(1): 519-521, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-995947